US20080215086A1 - Single disc intraluminal fixation patent foramen ovale closure device - Google Patents

Abstract

A device and method for deploying a mechanical closure device for closing a passageway in a body, for example a patent foramen ovale (PFO) in a heart. The single disc mechanical closure device is comprise of a distal and proximal anchor constrained by a closure line to facilitate mechanical closure by bringing the distal and proximal anchors into close proximity along the closure line.

Description

CROSS REFERENCE TO RELATED APPLICATION
• This application claims the benefit of U.S. Provisional Application Ser. No. 60/827,589 filed Sep. 29, 2006, which is incorporated by reference herein.
FIELD OF THE INVENTION
• This invention relates to devices for closing a passageway in a body, for example a patent foramen ovale (PFO) in a heart, and related methods of using such closure devices for closing the passageway.
BACKGROUND OF THE INVENTION
• Patent foramen ovale (PFO) is an anatomical interatrial communication with potential for right-to-left shunting of blood. Foramen ovale has been known since the time of Galen. In 1564, Leonardi Botali, an Italian surgeon, was the first to describe the presence of foramen ovale at birth. However, the function of foramen ovale in utero was not known at that time. In 1877, Cohnheim described paradoxical embolism in relation to patent foramen ovale.
• Patent foramen ovale is a flap-like opening between the atrial septa primum and secundum at the location of the fossa ovalis that persists after age one year. In utero, the foramen ovale serves as a physiologic conduit for right-to-left shunting of blood in the fetal heart. After birth, with the establishment of pulmonary circulation, the increased left atrial blood flow and pressure presses the septum primum (SP) against the walls of the septum secundum (SS), covering the foramen ovale and resulting in functional closure of the foramen ovale. This closure is usually followed by anatomical closure of the foramen ovale due to fusion of the septum primum (SP) to the septum secundum (SS).
• Where anatomical closure of the foramen ovale does not occur, a patent foramen ovale (PFO) is created. A patent foramen ovale is a persistent, usually flap-like opening between the atrial septum primum (SP) and septum secundum (SS) of a heart. A patent foramen ovale results when either partial or no fusion of the septum primum (SP) to the septum secundum (SS) occurs. In the case of partial fusion or no fusion, a persistent passageway (PFO track) exists between the septum primum (SP) and septum secundum (SS). This opening or passageway is typically parallel to the plane of the septum primum, and has a mouth that is generally oval in shape. Normally the opening is relatively long, but quite narrow. The opening may be held closed due to the mean pressure in the left atrium (LA) being typically higher than in the right atrium (RA). In this manner, the septum primum acts like a one-way valve, preventing fluid communication between the right and left atria through the PFO track. However, at times, the pressure may temporarily be higher in the right atrium, causing the PFO track to open up and allow some fluid to pass from the right atrium to the left atrium. Although the PFO track is often held closed, the endothelialized surfaces of the tissues forming the PFO track prevent the tissues from healing together and permanently closing the PFO track.
• Studies have shown that a relatively large percentage of adults have a patent foramen ovale (PFO). It is believed that embolism via a PFO may be a cause of a significant number of ischemic strokes, particularly in relatively young patients. It has been estimated that in 50% of cryptogenic strokes, a PFO is present. Blood clots that form in the venous circulation (e.g., the legs) can embolize, and may enter the arterial circulation via the PFO, subsequently entering the cerebral circulation, resulting in an embolic stroke. Blood clots may also form in the vicinity of the PFO, and embolize into the arterial circulation and into the cerebral circulation. Patients suffering a cryptogenic stroke or a transient ischemic attack (TIA) in the presence of a PFO often are considered for medical therapy to reduce the risk of a recurrent embolic event.
• Pharmacological therapy often includes oral anticoagulants or antiplatelet agents. These therapies may lead to certain side effects, including hemorrhage. If pharmacologic therapy is unsuitable, open heart surgery may be employed to close a PFO with stitches, for example. Like other open surgical treatments, this surgery is highly invasive, risky, requires general anesthesia, and may result in lengthy recuperation.
• Nonsurgical closure of a PFO is possible with umbrella-like devices developed for percutaneous closure of atrial septal defects (ASD) (a condition where there is not a well-developed septum primum (SP)). Many of these conventional devices used for ASD, however, are technically complex, bulky, and difficult to deploy in a precise location. In addition, such devices may be difficult or impossible to retrieve and/or reposition should initial positioning not be satisfactory. Moreover, these devices are specially designed for ASD and therefore may not be suitable to close and seal a PFO, particularly because the septum primum (SP) overlaps the septum secundum (SS).
SUMMARY OF THE INVENTION
• The present invention relates to devices for closing a passageway in a body, for example a patent foramen ovale (PFO) in a heart, and related methods of using such closure devices for closing the passageway. The closure device includes a closure line having a first and a second end. A first expandable tissue anchor is connected to the first end of the closure line, the tissue anchor being adapted to anchor within the PFO track. An second expandable anchor is located along the second end of the closure line, the second expandable anchor having a locking mechanism integrated therein. The locking mechanism is adapted to allow the closure line to uni-axially slide through the second expandable anchor in one direction, and prevent sliding movement in the opposite direction.
• Another embodiment of the invention includes a medical device for closing a luminal tissue passageway between a first and a second chamber in a body. The medical devices includes a closure line having a first end and a second end. A first expandable anchor is connected to the first end of the closure line, and has a plurality of tissue anchoring members adapted to pierce into tissue within the luminal passageway and subsequently expand to embed into the tissue. A second expandable anchor is located along the second end of the closure line, and is configured to substantially close open end of the passageway and inhibit fluid communication from the first chamber to the second chamber when the closure line is tensioned between the first expandable anchor and the second expandable anchor.
• Another embodiment of the invention includes a method of closing a luminal tissue passageway between a first and a second chamber in a body. The method includes the steps of locating a distal end of a closure device in the luminal passageway, the closure device having a closure line with proximal and distal ends, a first expandable anchor located along the distal end of the closure line, and a second expandable anchor located along the proximal end of the closure line. The first expandable anchor is deployed and anchored in the luminal passageway and the closure device is retracted through the luminal tissue passageway into the second chamber. The second expandable anchor is deployed in the second chamber adjacent to the end of the a luminal tissue passageway, and the closure line is tensioned between the first expandable anchor and the second expandable anchor.
BRIEF DESCRIPTION OF THE DRAWINGS
• FIG. 1 is a short axis view of the heart at the level of the right atrium (RA) and the left atrium (LA), in a plane generally parallel to the atrio-ventricular groove, and at the level of the aortic valve, showing a PFO track.
• FIG. 2 is a cross-sectional view of the PFO track ofFIG. 1 in a closed configuration.
• FIG. 3 is a close-up section view illustrating the PFO track held in the closed position by left atrial pressure.
• FIG. 4A is a cross-sectional view of the PFO track ofFIG. 2 in an open configuration.
• FIG. 4B is a close-up section view illustrating the PFO track in an open configuration.
• FIG. 5A is a cross-sectional view illustrating the PFO tract ofFIG. 1.
• FIG. 5B is a section view taken along line A-A inFIG. 4B.
• FIG. 5C is a section view taken along line A-A inFIG. 3.
• FIG. 5D is a close-up section view of the PFO track, showing the tunnel formed by the tissue extension.
• FIG. 6 illustrates the closure device deployed intraluminally within the PFO track illustrating the relationship between the components comprising the closure device and deployment device according to one aspect of the present invention.
• FIG. 7A is a perspective view illustrating a linear locking mechanism according to one embodiment of the present invention.
• FIG. 7B shows one embodiment of a locking device integrated into the proximal anchor according to one embodiment of the present invention.
• FIG. 7C shows one embodiment of a locking device operatively associated with a separate anchor member according to one embodiment of the present invention
• FIG. 8A is a perspective view illustrating an asymmetric proximal anchor member according to one embodiment of the present invention.
• FIG. 8B is a close-up perspective view illustrating an asymmetric proximal anchor member according to one embodiment of the present invention.
• FIG. 9 illustrates a PFO closure device deployed to close a PFO track in the presence of an atrial septal defect according to one embodiment of the present invention.
• FIG. 10A is a section view illustrating theclosure device600 loaded into adelivery device630 according to one embodiment of the present invention.
• FIG. 10B is a section view illustrating theclosure device600 loaded into adelivery device630 according to another embodiment of the present invention.
• FIG. 11 is a section view illustrating the cannular delivery device deployed into the left atrium according to one embodiment of the present invention.
• FIG. 12 is a section view illustrating the deployment of the distal anchor into the left atrium according to one embodiment of the present invention.
• FIG. 13 is a section view illustrating the proper deployment of the distal anchor into the left atrium and PFO track according to one embodiment of the present invention.
• FIG. 14 is a section view illustrating the initial deployment of the proximal anchor into the left atrium according to one embodiment of the present invention.
• FIG. 15 is a section view illustrating the closure device properly cinched in place according to one embodiment of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
• The various figures show embodiments of the patent foramen ovale (PFO) closure device and methods of using the device to close a PFO. The device and related methods are described herein in connection with mechanically closing a PFO. These devices, however, also are suitable for closing other openings or passageways, including other such openings in the heart, for example atrial septal defects, ventricular septal defects, and patent ducts arterioses, as well as openings or passageways in other portions of a body such as an arteriovenous fistula. The invention therefore is not limited to use of the inventive closure devices to close PFO's.
• A human heart has four chambers. The upper chambers are called the left and right atria, and the lower chambers are called the left and right ventricles. A wall of muscle called the septum separates the left and right atria and the left and right ventricles. That portion of the septum that separates the two upper chambers (the right and left atria) of the heart is termed the atrial (or interatrial) septum while the portion of the septum that lies between the two lower chambers (the right and left ventricles) of the heart is called the ventricular (or interventricular) septum.
• FIG. 1 illustrates a short-axis view of theheart100 at the level of the right atrium (RA) and left atrium (LA), in a plane generally parallel to the atrio-ventricular groove, and at the level of the aortic valve. This view is looking from caudal to cranial.FIG. 1 also shows the septum primum (SP)105, a flap-like structure, which normally covers theforamen ovale115, an opening in the septum secundum (SS)110 of theheart100. In utero, theforamen ovale115 serves as a physiologic conduit for right-to-left shunting of blood in the fetal heart. After birth, with the establishment of pulmonary circulation, the increased left atrial blood flow and pressure presses the septum primum (SP)105 against the walls of the septum secundum (SS)110, covering theforamen ovale115 and resulting in functional closure of theforamen ovale115. This closure is usually followed by anatomical closure of theforamen ovale115 due to fusion of the septum primum (SP)105 to the septum secundum (SS)110.
• The PFO results when either partial or no fusion of the septum primum105 to theseptum secundum110 occurs. When this condition exists, a passageway (PFO track)120 between the septum primum105 andseptum secundum110 may allow communication of blood between the atria. ThisPFO track120 is typically parallel to the plane of theseptum primum105, and has an opening that is generally oval in shape.FIG. 2 illustrates the opening of thePFO track120 as viewed from an end of the track. Normally the opening is relatively tall, but quite narrow. The opening may be held closed by the mean pressure in the left atrium, which is typically higher than the right atrium.FIG. 3 is a close-up section view of thePFO track120 held in the closed position by left atrial pressure. In this position, the septum primum105 acts like a one-way valve, preventing fluid communication between the right and left atria through thePFO track120. Occasionally, the pressure in the right atrium may temporarily be higher than the left atrium. When this condition occurs, thePFO track120 opens and allow some fluid to pass from the right atrium to the left atrium, as indicated inFIGS. 4A and 4B. In particular,FIG. 4A is a cross-sectional view showing the PFO track ofFIG. 2 in an open configuration. Similarly,FIG. 4B is a close-up section view illustrating the PFO track in an open configuration.
• Although thePFO track120 is often held closed, the endothelialized surfaces of the tissues forming thePFO track120 prevent the tissue from healing together and permanently closing thePFO track120. As can be seen inFIGS. 5A-5C, (a view from line “C-C” ofFIG. 1), theseptum primum105 is firmly attached to theseptum secundum110 around most of the perimeter of theFossa Ovalis115, but has an opening along one side. The septum primum105 is often connected, as shown, by two or more extensions of tissue along the sides of thePFO track120 forming a tunnel.FIG. 5D is a magnified section view of thePFO track120, showing the tunnel formed by the tissue extensions. Typically, the tunnel length in an adult human can range between 2 and 13 mm.
• The present invention relates to a system and method for closing a passageway in a body. In a particular embodiment, the device is used to close the Patent Foramen Ovale in a human heart. One of ordinary skill in the art would understand that similar embodiments could be used to close other passageways and openings in the body without departing from the general intent or teachings of the present invention.
• FIG. 6 illustrates a device used to close the PFO according to one embodiment of the present invention. Thedevice600 comprises aflexible closure line625 coupled to twoexpandable anchors620,621.Anchor620 is a tissue anchor coupled to the distal end of theclosure line625 and is intended to provide distal fixation to adjacent connective tissue surfaces of either or both theseptum secundum110 and septum primum105 at a point within the luminal pathway of thePFO track120. In one embodiment, thedistal anchor member620 comprises a main body having a needle like projections orbarbs622 that project outward from the main body and are capable of penetrating the septum (septum secundum110 and/or the septum primum105) from within thePFO track120. The characteristics of thebarbs622 are such that after delivery of the anchor into the septum tissue, thebarbs622 extend outward in a radial direction and prevent thedistal anchor member620 from being withdrawn from the tissue—very similar to the barb integrated into a fish hook.
• Anchor621 is an expandable structure coupled to the proximal end of theflexible closure line625.Anchor621 is further sized and adapted to exert a compressive force along theseptum secundum110 and/or theseptum primum105, inducing natural occlusion of the PFO track, when operated in conjunction withanchor620 andclosure line625.Anchor621 is capable of sliding alongclosure line625 and locking in desired location to cinch or take-up slack inclosure line625 length, bringing the proximal anddistal anchors621,620 respectively, closer together and effectively bringing theseptum secundum110 and the septum primum105 in close proximity.Anchor621 may also be sized and shaped to substantially occlude the entrance to thePFO tunnel120 when cinched in place.
• In a preferred embodiment, the distal andproximal anchors621,620 respectively, are geometrically configured to suitably conform to the intended spatial features of the septal wall, wherein the septal wall is comprised of theseptum secundum110 andseptum primum105.
• FIG. 7A illustrates, in one preferred embodiment, the uni-axial cinching andpositional retention mechanism627 that works with theclosure line625 to bring and lock thedistal anchor620 andproximal anchor621 in close proximity. The locking is achieved by a mechanical appendage ortang628 that is configured to mechanically impinge upon theclosure line625, imparting a retention force directionally upon theclosure line625 to maintain the desired degree of cinching between both thedistal anchor620 and theproximal anchor621.
• Thelocking mechanism627 is operatively incorporated into theanchor member621 to secure theanchor member621 to theclosure line625. In one embodiment, the locking member may be an integral part of theanchor member621, formed into the hub of theanchor member621. In another embodiment of the invention, thelocking mechanism627 may be a functionally separate component or member that although is physically a separate member, is functionally integrated with theanchor member621. That is to say, thelocking mechanism627 can secure to theclosure line625 and prevent relative movement between theclosure line625 and theanchor member621 when the hub of theanchor member621 comes in contact with thelocking mechanism627.
• FIG. 7B is an isometric view of ananchor member621 with alocking mechanism627 integrated into the anchor member's621 proximal end. Similarly,FIG. 7C is an isometric view of ananchor member621 operatively associated with a separate anddistinct locking mechanism627 along aclosure line625. In this embodiment, thelocking mechanism625 secures to theclosure line625, and effectively secures theanchor member621 relative theclosure line625 when thehub621aof theanchor member621 comes in contact with thelocking mechanism627.
• In one embodiment, thelocking mechanism627 allows theclosure line625 to slide throughanchor member621 in one direction, and prevent sliding movement in the opposite direction. Examples of functionally similar commercial locking mechanisms include the DePuy Mitek RAPIDLOC™ device; zip ties; and similar linear locking devices known in the art. In a preferred embodiment of thelocking mechanism627, mechanical appendage ortang628 is used to lock onto theclosure line625 by having small finger-like protrusions that impinge on and push between the individual woven strands of theclosure line625.
• It should be noted that theseptum secundum110 and the septum primum105 do not have to be tightly touching to effect proper closure of the PFO. Instead, theseptum secundum110 and theseptum primum105 must just be brought close enough to minimize flow from atria to atria (typically flow from left atria to right atria).
• Alternatively, theanchor621 may be fixed to theclosure line625 at a predetermined distance fromanchor620. This may particularly be the case when theclosure line625 has an elastic or recoil ability and is capable of exerting tension when deployed, pulling theanchors620,621 together and effectively compressing the septum primum105 to theseptum secundum110. In still a further embodiment of the invention, aclosure device600 may include anelastic closure line625 and aslideable anchor621. In this embodiment, theanchor621 is capable of allowing theflexible closure line625 to slide through theanchor621 in one direction, and prevent sliding movement in the opposite direction, while theclosure line625 exerts tension between the twoanchors620,621. These configurations should not necessarily be considered limiting, and other combinations of components are contemplated, such as, for example, bothanchors620 and621 being slideable along a substantially elastic orinelastic closure line625.
• Theclosure line625 may be any biocompatible filament known in the art that is capable of securing the septum primum105 to theseptum secundum110. In a preferred embodiment theclosure line625 is a surgical suture, such as a multifilament non-biodegradable suture, or a forced entangled fiber filament. Alternatively, theclosure line625 may be made from an elastic material capable of exerting tension when stretched. In yet another alternative embodiment, theclosure line625 may be geometrically configured to exhibit structurally elastic behavior. In another alternative embodiment, theclosure line625 may be made from an anelastic material such as elastomeric polymers that are capable of exerting tension when stretched. In yet another alternative embodiment, theclosure line625 may be made from a super elastic material such as a nickel titanium alloy.
• Theanchors620,621 are expandable from a first, predeployed unexpanded configuration to a second expanded configuration. Theanchors620,621 are preferably constructed from a structurally deformable material.
• Structurally deformable materials are materials that can elastically or plastically deform without compromising their integrity. Geometric structures, such asanchors620,621, made from a deformable material are capable of changing shape when acted upon by an external force, or removal or an external force.
• Geometric structures made from structurally deformable materials are typically self expanding or mechanically expandable. In a preferred embodiment, theanchors620,621 are made from a self-expanding material, such as Nitinol or a resilient polymer. However, the self-expandinganchors620,621 may also be made from an elastically compressed spring temper biocompatible metals. These self-expanding structures are held in a constrained configuration by an external force, typically a capture sheath, and elastically deform when the constraining force is released.
• Some structurally deformable materials may also be mechanically expandable. Geometric structures can be mechanically expanded by introduction of an external force, through, for example, a mechanical expansion means. Mechanical expansion means are well known in the art and include balloon or cage expansion devices.
• Once an external mechanical force is introduced to the geometric structure, the structure plastically deforms to its desired final configuration.
• The proximal anddistal anchors620,621 in their constrained state are capable of being held in a restrained low profile geometry for delivery, and assume an expanded shape capable of preventing theanchor620,621 from retracting through thePFO Track120, as the case may be, once deployed.
• In a preferred embodiment, theanchors620,621 are cut from a Nitinol hypotube700 by methods known in the art.
• Nitinol is utilized in a wide variety of applications, including medical device applications as described above. Nitinol or NiTi alloys are widely utilized in the fabrication or construction of medical devices for a number of reasons, including its biomechanical compatibility, its biocompatibility, its fatigue resistance, its kink resistance, its uniform plastic deformation, its magnetic resonance imaging compatibility, its ability to exert constant and gentle outward pressure, its dynamic interference, its thermal deployment capability, its elastic deployment capability, its hysteresis characteristics, and is moderately radiopaque.
• Nitinol, as described above, exhibits shape memory and/or super-elastic characteristics. Shape memory characteristics may be simplistically described as follows. A metallic structure, for example, a Nitinol tube that is in an Austenitic phase may be cooled to a temperature such that it is in the Martensitic phase. Once in the Martensitic phase, the Nitinol tube may be deformed into a particular configuration or shape by the application of stress. As long as the Nitinol tube is maintained in the Martensitic phase, the Nitinol tube will remain in its deformed shape. If the Nitinol tube is heated to a temperature sufficient to cause the Nitinol tube to reach the Austenitic phase, the Nitinol tube will return to its original or programmed shape. The original shape is programmed to be a particular shape by well-known techniques.
• Super-elastic characteristics may be simplistically described as follows. A metallic structure for example, a Nitinol tube that is in an Austenitic phase may be deformed to a particular shape or configuration by the application of mechanical energy. The application of mechanical energy causes a stress induced Martensitic phase transformation. In other words, the mechanical energy causes the Nitinol tube to transform from the Austenitic phase to the Martensitic phase. By utilizing the appropriate measuring instruments, one can determined that the stress from the mechanical energy causes a temperature drop in the Nitinol tube. Once the mechanical energy or stress is released, the Nitinol tube undergoes another mechanical phase transformation back to the Austenitic phase and thus its original or programmed shape. As described above, the original shape is programmed by well know techniques. The Martensitic and Austenitic phases are common phases in many metals.
• Medical devices constructed from Nitinol are typically utilized in both the Martensitic phase and/or the Austenitic phase. The Martensitic phase is the low temperature phase. A material is in the Martensitic phase is typically very soft and malleable. These properties make it easier to shape or configure the Nitinol into complicated or complex structures. The Austenitic phase is the high temperature phase. A material in the Austenitic phase is generally much stronger than the material in the Martensitic phase. Typically, many medical devices are cooled to the Martensitic phase for manipulation and loading into delivery systems. When the device is deployed at body temperature, they return to the Austenitic phase.
• Other materials that have shape memory characteristics may also be used, for example, some polymers and metallic composition materials. It should be understood that these materials are not meant to limit the scope of the invention.
• Once the proximal anddistal members621,620 are cut from the Nitinol hypotube, they are formed into a desired expanded configuration and annealed to assume a stress-free (relaxed) state. In one embodiment of the invention, thedistal anchor member620 is formed into an anchor shaped configuration, having a plurality of pointed legs withbarbs622 that can puncture and anchor in tissue. Correspondingly, in this embodiment, theproximal member621 is formed into a slightly concaved woven-looking basket that could flatten into a woven-looking disc when pulled against the septal wall. A perspective view of the expandedtissue anchor620 anchored into the adjacent connective tissue surfaces of either or both theseptum secundum110 and septum primum105 at a point within the luminal pathway of thePFO track120 is illustrated inFIG. 6.
• Theproximal anchor621 is a basket-like device capable of laterally expanding to anchor the closure device against the septum (i.e. septum secundum110 and/or septum primum105). In a preferred embodiment, theproximal anchor621 has a diametric expansion ratio of approximately five (5) to approximately twenty-five (25) to one (1). Theproximal anchor621 may additionally act as an occluder to substantially occlude or shunt blood flow through thePFO track120. To assist the occlusionaly characteristics theproximal anchor member621 may or may not be coated or covered with a biocompatible polymeric fabric that could assist in occluding blood flow into the tunnel. In the case that theproximal anchor member621 is not covered, blood flow shunting through thePFO track120 might not decrease as rapidly as it would in the covered case, however eventually the incorporation of theproximal anchor621 would block a sufficient amount of flow such that the PFO track (tunnel)120 would be substantially closed or considered closed.
• Once theclosure device600 is deployed, the basket shapedanchor621 collapses under tensioning of theclosure line625, into a flattened “flower petal” or basket shape as illustrated inFIG. 6. In this state, theanchors620,621 are under strain. The super elastic properties of theanchors620,621 under strain exert an axially outward force against the adjacent tissue, putting theclosure line625 in tension.
• This anchor design should not be considered a limiting feature of the invention, as other shapes and configurations of anchors are also contemplated by the present design. This may include, for example, expandable disc design, star design, j-hook design, or any expandable geometric shape. In addition other materials exhibiting similar characteristics, such as non-biodegradable swellable polymers, are similarly contemplated by the present invention.
• FIGS. 8A and 8B illustrate anclosure device600 having an asymmetricproximal anchor member621 according to another embodiment of the present invention. In the illustrated embodiment, theproximal anchor member621 is asymmetric about the hub incorporatinglocking mechanism627. This asymmetry may allow themember621 to more closely conform the shape of the surrounding tissue, taking advantage of the atrial anatomy.
• ThePFO closure device600 can be used to facilitate closing thePFO track120 when other defects in the septal wall are present. For example, thePFO closure device600 may be used when an atrial septal aneurysm (ASA) is present. An ASA is characterized as a saccular deformity, generally at the level of the fossa ovale, which protrudes to the right or left atrium, or both.FIG. 9 illustrates thePFO closure device600 deployed to close aPFO track120 in the presence of an atrial septal defect.
• The present invention utilizes a removable deployment device to introduce themechanical closure device600 into the atrium of the heart, preferably through a minimally invasive, transluminal procedure.
• FIGS. 10A and 10B are section views illustrating theclosure device600 loaded into adelivery device630 according to two embodiments of the present invention. In each embodiment thedelivery device630 includes an outer tubular structure orcatheter635 and an innertubular structure636. Thedelivery device630 may also include a guidewire lumen (not shown) to allow thedelivery device630 to track over a guidewire (not shown). The innertubular structure636 is slideably engaged within the outertubular structure635 and acts as a “pusher” to deploy theclosure device600 from the distal end of the outertubular structure635. In the embodiment illustrated inFIG. 10A, the innertubular structure636 is sized to push against the proximal end of theoccluder621, causing theoccluder621 to be displaced distally, and subsequently displacing thedistal anchor member620 from the distal end of the outertubular structure635. Similarly, in the embodiment illustrated inFIG. 10B, the innertubular structure636 is sized be slideably engaged with theproximal occluder621, and to push against the proximal end of thedistal anchor620, causing thedistal anchor member620 be displaced distally. As thedistal anchor620 is distally displaced, theproximal occluder member621 is similarly displaced—by virtue of its relative position within the innertubular structure636, or alternatively, because it is operatively connected to thedistal anchor ember620 via theclosure line625.
• Minimally invasive heart surgery refers to several approaches for performing heart operations that are less difficult and risky than conventional open-heart surgery. These approaches restore healthy blood flow to the heart without having to stop the heart and put the patient on a heart-lung machine during surgery. Minimally invasive procedures are carried out by entering the body through the skin, a body cavity or anatomical opening, but with the smallest damage possible to these structures. This results in less operative trauma for the patient. It also less expensive, reduces hospitalization time, causes less pain and scarring, and reduces the incidence of complications related to the surgical trauma, speeding the recovery.
• One example of a minimally invasive procedure for performing heart surgery is a trans-thoracic laparoscopic (endoscopic) procedure. The part of the mammalian body that is situated between the neck and the abdomen and supported by the ribs, costal cartilages, and sternum is known as the thorax. This division of the body cavity lies above the diaphragm, is bounded peripherally by the wall of the chest, and contains the heart and lungs. Once into the thorax, the surgeon can gain access to the atrium of the heart through an atriotomy, a surgical incision of an atrium of the heart. For example, if the surgeon wishes to gain access to the right atrium they will perform an atriotomy in the right atrial appendage.
• The primary advantage of a trans-thoracic laparosopic procedure is that there is no need to make a large incision. Instead, the surgeon operates through 3 or 4 tiny openings about the size of buttonholes, while viewing the patient's internal organs on a monitor. There is no large incision to heal, so patients have less pain and recover sooner. Rather than a 6- to 9-inch incision, the laparoscopic technique utilized only 4 tiny openings—all less than ½ inch in diameter.
• Another minimally invasive technique for gaining access to the heart and deploying the closure device is a percutaneous transluminal procedure. Percutaneous surgical techniques pertain to any medical procedure where access to inner organs or other tissue is done via needle-puncture of the skin, rather than by using an “open” approach where inner organs or tissue are exposed (typically with the use of scalpel). The percutaneous approach is commonly used in vascular procedures, where access to heart is gained through the venous or arterial systems. This involves a needle catheter getting access to a blood vessel, followed by the introduction of a wire through the lumen of the needle. It is over this wire that other catheters can be placed into the blood vessel. This technique is known as the modified Seldinger technique. ThePFO closure device600 may also be deployed via percutaneous methods by steerable catheters or guidewires.
• In the Seldinger technique a peripheral vein (such as a femoral vein) is punctured with a needle, the puncture wound is dilated with a dilator to a size sufficient to accommodate an introducer sheath, and an introducer sheath with at least one hemostatic valve is seated within the dilated puncture wound while maintaining relative hemostasis.
• In one embodiment of the invention, a deployment system is configured to facilitate the approach and transluminal access of the luminal pathway of thePFO track120, however other configurations and shaped structures may be used as would be understood by one skilled in the art.
• As previously described thedelivery device630 illustrated inFIGS. 10A and 10B is a substantially rigid structure capable of navigating the tortuous vasculature and transluminally entering thePFO track120. The delivery system is preferably sized to be 13 French or smaller, most preferably 10 French or smaller, and made from a biocompatible material, such as, for example biocompatible polymeric materials, such as, Pebax (Nylon) and Polyurethane. It should be understood that these materials are not meant to limit the scope of the invention. Any biocompatible material capable of having sufficient material attributes to facilitate navigation and transluminal access of thePFO track120 may be suitable. Thedelivery system630 is typically constructed with an axially and circumferentially reinforcing infrastructure, as is known in the art. In addition, thedelivery device630 is tapered at the distal end, as is known in the art. In a preferred embodiment, the geometric configuration of the tapered distal end is optimized to minimize tissue trauma at the site of luminal entry.
• As illustrated inFIGS. 10A and 10B, theclosure device600 is loaded in thedelivery device630 for deployment transluminally into thePFO track120. That is to say, thedistal anchor620 is loaded along the distal end of thedelivery device630, and connected to theproximal anchor621 via theclosure line625. Theouter sheath635 of thedelivery device630 maintains the proximal anddistal anchors621,620 is a substantially constrained, collapsed condition prior to delivery.
• With the introducer sheath in place, the guide catheter ordelivery member630 of the closure device is introduced through the hemostatic valve of the introducer sheath and is advanced along the peripheral vein, into the region of the vena cavae, and into the right atrium.
• Thedelivery device630 is then advanced distally into thePFO track120 that defines the luminal space between the septum primum105 and orseptum secundum110. A separate guidewire may also be advanced with thedelivery device630 through thePFO Track120 to provide additional luminal guidance. Thedelivery device630 is seated in thePFO track120, thereby providing access forclosure devices600 through its own inner lumen into thePFO track120.FIG. 11 is a section view illustrating thedelivery device630 deployed into thePFO track120 according to one embodiment of the present invention.
• It is however further contemplated that other left atrial access methods may be suitable substitutes for using thedelivery device630 andclosure device600 of the present invention. In one alternative variation not shown, a “retrograde” approach may be used, wherein thedelivery device630 is advanced into the left atrium from the arterial system. In this variation, the Seldinger technique is employed to gain vascular access into the arterial system, rather than the venous, for example, at a femoral artery. Thedelivery device630 is advanced retrogradedly through the aorta, around the aortic arch, into the ventricle, and then into the left atrium through the mitral valve.
• Once in the desired atrium of the heart theclosure device600 is deployed transluminally into the tissue comprising thePFO track120. For the purpose of this invention, transluminal deployment is defined as deployment from one atrial chamber to the lumen or tunnel of thePFO tract120, i.e. into the luminal space created by thePFO track120 that exists between the septum primum (SP)105 and/or septum secundum (SS)110, or visa versa, whichever the case may be.
• By way of example, in one embodiment of the present invention using right atrial access, the right atrium is first accessed by the delivery device630 (and closure device600). Theclosure device600 may then be deployed by transluminally accessing the luminal pathway of thePFO track120 from the right atrial chamber, and deploying thedistal anchor620 associated with theclosure device600 into the septum primum105 and/orseptum secundum110 encompassing thePFO track120.FIG. 12 is a section view illustrating the deployment of thedistal anchor620 into the luminal pathway comprising thePFO track120 according to one embodiment of the present invention.
• After successful deployment of thedistal anchor620, thedelivery device630 may be partially withdrawn from thePFO track120 to the right atrial chamber, leaving thedistal anchor620 in place.FIG. 13 is a section view illustrating the proper deployment of thedistal anchor620 into thePFO track120 according to one embodiment of the present invention.
• Theproximal anchor621 associated with theclosure device600 can then be deployed into the right atrial chamber. This substantially linear atrial deployment method is shown inFIG. 14.
• Similar procedures are employed when a left atrial access technique is used.
• In either case, once the proximal anchor is deployed, the closure device may be cinched to bring the proximal anddistal anchors621,620 closer together. This results in theseptum secundum110 and theseptum primum105 being brought in close proximation to facilitate closure of the Patent Foramen Ovale. It should be noted that theseptum secundum110 and the septum primum105 do not have to be tightly touching to effect proper closure of the PFO. Instead, theseptum secundum110 and theseptum primum105 must just be brought close enough to minimize flow from atria to atria (typically flow from right atria to left atria). In addition, if theproximal anchor621 is being used as an occluder, substantially occlusion or shunting of thePFO track120 may be accomplished by theanchor621 substantially covering the entrance to thePFO track120.
• To achieve and maintain the proximity between theseptum secundum110 and theseptum primum105, it may be necessary to adjust theproximal anchor621 by uni-axially cinching or sliding theproximal anchor621 alongclosure line625. In one embodiment of the invention, cinching comprises uni-axially adjusting theproximal anchor621 relative to aclosure line625 associated with theclosure device600. In another embodiment of the invention, cinching comprises incrementally adjusting theproximal anchor621 relative to theclosure line625 associated with theclosure device600.FIG. 15 is a section view illustrating theclosure device600 properly cinched in place according to one embodiment of the present invention.
• Once the closure device is cinched in place the method may further comprise assessing the degree of proximation between theseptum secundum110 and theseptum primum105.
• In one embodiment of the invention, the clinician may visually assess the proximation though an endoscopic or fluoroscopic procedure. In addition, other methods may be used to measure the proximation between theseptum secundum110 and theseptum primum105, such as through pressure observation or infrared imaging.
• After proper cinching, any unwanted length ofclosure line625 that remains unconstrained within the right atrium may be mechanically removed. Devices known in the art capable of removing theexcess closure line625 include catheter-based snare and cut devices. In addition to independent devices, a mechanical cut and removal mechanism may be integrated into the deployment device.
• The closure device will then be in position, with theanchors620,621 in place and theclosure line625 connecting theanchors620,621. The restrainingmechanism627 withintegrated tang628 mechanically acts upon theclosure line625 thus holding the septum primum105 in place.
• Another embodiment of the invention may include a location monitoring system to facilitate placement of thedeployment device630. In particular, the location monitoring device will assist in determining whether the clinician is in the correct chamber of the heart.
• In a preferred embodiment, the location monitoring system includes the ability to measure localized pressure relative to the distal end of the deployment device630 (not shown by illustration). The pressure measurement read by the location monitoring system may be achieved by electronic, mechanical and/or physical means, such as a solid-state pressure transducer, spring loaded diaphragm, hydraulic pressure port, and/or communicating manometer. These and other pressure measurement techniques would be known by one of skill in the art.
• By way of example it is well known that pressures vary in different locations within the cardiovascular system. Specifically, gage pressure in the right and left atrium are know to range from approximately 1-6 mmHg to 10 mmHg respectfully. Similarly, gage pressure within the ascending aorta ranges from approximately 120 to 160 mmHg during systole.
• Before deployment, the clinician will first monitor pressure within the right atrium. This reading should indicate a pressure of 1-6 mmHg. The distal end of thedelivery device630 will be inserted transluminally into the PFO track120 (luminal opening between the septum primum105 and/or septum secundum110). The monitored pressure should remain constant. A higher reading, in the range of approximately 6-12 mmHg indicates thedelivery device630 has exited the distal end of thePFO track120 and is located in the left atrium. A much higher reading, such as in the range of approximately 120 to 160 mmHg, indicates unintended puncture or dissection of the aorta. The clinician will then have to retract thedelivery device630 and reposition thedelivery device630 for re-entry. The clinician should observe a pressure change to 1-6 mmHg.
• For delivery to the heart, thedeployment device600 is used in conjunction with an accessory device (not shown) known in the art. In a preferred embodiment, the accessory device may be a guiding catheter that tracks over a guidewire, and is steered through the vasculature into the right atrium (not shown in illustration).
• In another embodiment, the accessory device anddeployment device630 may be formed as an integrated component, capable of being steered through the vasculature (not shown in illustration).
• To facilitate deployment of theclosure device600, thedeployment device630 may include features that provide backup support. This backup support may include, for example: an axially asymmetric expansion member attached to thedeployment device630, such as a balloon or self expanding cage (not shown in illustration); a spline (not shown in illustration); or imparting an assymetric shape along the body of the deployment device630 (not shown in illustration). These and other such backup support devices would be understood by one of skill in the art. These backup support features can also be incorporated onto accessory devices, such as the guide catheter.
• Still other embodiments utilizing known methods and apparatus to deliver thedeployment device630 andclosure device600 into the atrium ofheart100 would be obvious to one of skill in the art.
• In yet another preferred embodiment, theproximal anchor621 may be covered with a biocompatible polymeric fabric (not shown in the corresponding illustration) on one or more surfaces that are exposed in either an orthogonal or oblique manner (off-axis in the axial direction of the luminal PFO track) to the opening of the luminal PFO track. In another embodiment, the biocompatible polymeric fabric may resorb into the body as a result of time. In yet another embodiment, the biocompatible polymeric fabric may resorb into the body as a result of applied stress. In yet another embodiment, the biocompatible polymeric fabric may resorb into the body as a result of both time and applied stress.
• It should be understood that these materials are not meant to limit the scope of the invention. Any biocompatible material capable of having sufficient material attributes to aide in promoting reduction of hemodynamic flow from one atrial chamber to the other through thetransluminal PFO track120, through theseptum secundum110 and/or septum primum105, by either simple flow perturbance or by enhancing the biological healing process, may be suitable.
• These and other objects and advantages of this invention will become obvious to a person of ordinary skill in this art upon reading of the detailed description of this invention including the associated drawings.
• Various other modifications, adaptations, and alternative designs are of course possible in light of the above teachings. Therefore, it should be understood at this time that within the scope of the appended claims the invention might be practiced otherwise than as specifically described herein.

Claims (21)

1. A medical device for closing a luminal tissue passageway between a first and a second chamber in a body, the luminal tissue passageway having first and second open ends, comprising:

a closure line having a first end and a second end;

a first expandable anchor connected to the first end of the closure line, the first expandable anchor having a plurality of tissue anchoring members adapted to pierce into tissue within the luminal passageway and subsequently expanding to embed into the tissue; and

a second expandable anchor located along the second end of the closure line, the second expandable anchor configured to substantially close the second open end of the passageway and inhibit fluid communication from the first chamber to the second chamber when the closure line is tensioned between the first expandable anchor and the second expandable anchor.

2. The medical device ofclaim 1 wherein the second expandable anchor substantially prevents fluid communication from the first chamber to the second chamber by collapsing the second open end of the passageway.

3. The medical device ofclaim 1 wherein the second expandable anchor substantially prevents fluid communication from the first chamber to the second chamber by occluding the second open end of the passageway.

4. The medical device ofclaim 1 further comprising a locking mechanism operatively associated with the second expandable anchor, the locking mechanism allowing the closure line to uni-axially slide through the second expandable anchor in one direction, and prevent sliding movement in the opposite direction.

5. The medical device ofclaim 1 wherein the closure line is elastic.

6. The medical device ofclaim 1 wherein the closure line is a biocompatible filament.

7. The medical device ofclaim 6 wherein the biocompatible filament is a surgical suture.

8. The medical device ofclaim 7 wherein the surgical suture is a multifilament non-biodegradable suture.

9. The medical device ofclaim 7 wherein the surgical suture is a forced entangled fiber filament.

10. The medical device ofclaim 1 wherein at least one of the first or the second expandable anchors are made from a structurally deformable material.

11. The medical device ofclaim 1 wherein at least one of the first expandable anchor and the second expandable anchor are self-expanding.

12. The medical device ofclaim 1 wherein the second expandable anchor is covered with a biocompatible fabric.

13. The medical device ofclaim 12 wherein the biocompatible fabric is made from a non-biodegradable polymeric fabric.

14. The medical device ofclaim 12 wherein the biocompatible fabric is made from a biodegradable polymeric fabric.

15. The medical device ofclaim 14 wherein the biodegradable polymeric fabric resorbs into the body as a function of time.

16. The medical device ofclaim 14 wherein the biodegradable polymeric fabric resorbs into the body as a function of applied stress.

17. The medical device ofclaim 1 wherein the at least one of the first expandable anchor and the second expandable anchor are made from a super elastic material.

18. The medical device ofclaim 1 wherein at least one of the first expandable anchor and the second expandable anchor are mechanically expandable.

19. The medical device ofclaim 18 wherein the at least one of the mechanically expandable first expandable anchor and second expandable anchor are made from a plastically deformable material.

20. A method of closing a luminal tissue passageway between a first and a second chamber in a body, the luminal tissue passageway having a first and a second open end, comprising:

locating a distal end of a closure device in the luminal passageway, the closure device having a closure line with proximal and distal ends, a first expandable anchor located along the distal end of the closure line, and a second expandable anchor located along the proximal end of the closure line;

deploying the first expandable anchor in the luminal passageway;

anchoring the first expandable anchor in the luminal passageway;

retracting the closure device through the luminal tissue passageway into the second chamber;

deploying the second expandable anchor in the second chamber adjacent to the second end of the a luminal tissue passageway; and

tensioning the closure line between the first expandable anchor and the second expandable anchor.

21. The method ofclaim 20 wherein tensioning the closure line comprises unilaterally distally displacing the second expandable anchor along the closure line.

Images